To pharmacologically antagonize the MDM2/X-p53 (hDM2/X-p53 in human) interaction, involved in many cancers, several small-molecules have been developed, such as Nutlin-3 and its derivatives [254,255,256,257]. This evidence concerns the gene TP53 and cancer.